MedTrace Logo

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

NCT01451736 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2022-04-11

No results posted yet for this study

Summary

This study will determine the efficacy of oral risperidone (Risperdal) versus long-acting injectable paliperidone palmitate (Invega Sustenna) in treating people with first-episode schizophrenia.

Conditions

  • Schizophrenia (Recent-onset)

Interventions

DRUG

paliperidone palmitate

long-acting injectable

DRUG

risperidone

oral

Sponsors & Collaborators

Principal Investigators

  • Keith H Nuechterlein, Ph.D. · University of California, Los Angeles (UCLA) Semel Institute for Neuroscience and Human Behavior

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2021-12-01
Completion
2021-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01451736 on ClinicalTrials.gov